Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/185—Magnoliopsida (dicotyledons)
  • A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
  • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
  • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/185—Magnoliopsida (dicotyledons)
  • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
  • A61K36/232—Angelica
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/185—Magnoliopsida (dicotyledons)
  • A61K36/82—Theaceae (Tea family), e.g. camellia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
  • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
  • A61K9/1605—Excipients; Inactive ingredients
  • A61K9/1629—Organic macromolecular compounds
  • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
  • A61K9/1682—Processes
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/10—Laxatives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/06—Antianaemics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

• the present invention relates to an oral composition obtained by granulating a powdered oral material using an oligosaccharide solution as a binder and a method for producing the same.
• binders widely used for granulating powdered oral materials are hydroxypropylcellulose, hydroxypropenoremethinoresenorelose, methinoresenorelose, canoleboxymethinoresenorelose, punoreran, starch, dextrin It is widely known that good condyles can be obtained by using these binders.
• oligosaccharides are known to act in the large intestine after ingestion and selectively proliferate Bifidobacteria, which are useful in the intestines.
• oligosaccharides have excellent sweetness, it has been reported that they can be used in various foods for the purpose of improving taste (see JP-A-10-20957 and JP-A-2004-161701).
• oligosaccharides have the property of being easily wetted by water and contribute to improvement of moldability by adding supplementary to the binder during molding (PCT WO 00/48575).
• an oligosaccharide solution when a powdered oral material is molded (granulated), can be used as a binder so that the powder can be molded (granulated) without using a binder other than oligosaccharide.
• the present invention provides a granular oral composition having a good mouth feel when suspended in liquid and non-suspended.
• the present inventor has eagerly studied to mold (granulate) powdered oral materials using food materials that have useful functions in vivo and are required to be consumed by consumers.
• an oligosaccharide solution as a binder, not only can it be sufficiently molded (granulated), it has a good mouthfeel when suspended in liquid, and it retains in the oral cavity when liquid is not suspended. It was possible to obtain a granular oral composition with improved s.
• the present invention is a method for producing a granular oral composition comprising granulating a powdered oral material using an oligosaccharide solution.
• the oral composition according to the present invention can be obtained by using an oligosaccharide solution as a binder for a powdered oral material and can be further ingested as a food or drink.
• the oligosaccharide used in the present invention does not depend on either a homo-oligosaccharide or a hetero-oligosaccharide, and a plurality of monosaccharides are linked by glycosyl bonds (preferably at a disaccharide to decasaccharide level. Bond) A short sugar chain.
• raffinose palatinose, latathitol, lactulose, ratatosucrose, stachyose, raftylose, galatato-oligosaccharide, transfer galactooligosaccharide, gentio-oligosaccharide, furata-oligosaccharide, -gelooligosaccharide, xylooligosaccharide, maltooligosaccharide, cellooligosaccharide, noratinose Oligosaccharides, isomalt-oligosaccharides and soybean oligosaccharides.
• These oligosaccharides may be used in combination of two or more, and any one d-form can be used. Of these, it is desirable to use xylo-oligosaccharides.
• Xylooligosaccharide refers to an oligosaccharide in which xylose is linked with several ⁇ -1,4 bonds, using corn cob, homopolysaccharide xylan (hicelle mousse) from which cotton shell husk can be obtained.
• An odorless crystalline powder that is white and has a strong sweetness.
• the oligosaccharide is used in a solution state, and preferably exhibits the role of a spray liquid simultaneously with the role of a binder.
• the solvent that dissolves the oligosaccharide is an aqueous solvent, such as water or hydrous ethanol.
• the concentration of the oligosaccharide in the oligosaccharide solution should be a concentration that simultaneously functions as a binder and a granulating water. The concentration depends on the type of oligosaccharide used and the oral powder material to be granulated. Easily selectable. For example, when granulating a food fiber-containing material, the preferred oligosaccharide concentration is 5 to 40% by weight.
• the content of these oligosaccharides in the oral composition can be appropriately determined as a normal dose according to the purpose of blending, and the total amount of oligosaccharides is 0.1 to 30% by weight, more preferably 1 -20% by weight, particularly preferably 3-15% by weight.
• the intake of oligosaccharide is 0.1 to 10 g per adult, preferably 0.3 to 0.8 g. It is good to decide as a guideline.
• the oral material is a substance that is expected to have an effect as a food, drink, health food, or pharmaceutical product, that is, a substance having biofunctionality, and is a material that is taken into the body through the loca gastrointestinal tract.
• the oral material is in powder form, it is easy to scatter, There are cases where handling and ingestion through the mouth may be a problem, but even if an attempt is made to make it liquid for easy ingestion, it may take a long time to dissolve if it is insoluble or hardly soluble in an aqueous solvent. There is a problem. These problems are particularly serious in children and the elderly, and it is necessary to granulate them for easy use. Even in the case of an oral material that is not in powder form, it can be granulated by the method of the present invention after being converted to a powder of 75 m or less by various methods.
• the powdered oral material to be granulated in the present invention is not particularly limited, but an oral material particularly suitable for the method of the present invention contains a water-insoluble component.
• water-insoluble components include fat-soluble vitamins and insoluble dietary fibers, and examples of oral materials containing these include dietary fiber-containing materials.
• the main effects of dietary fiber are an increase in fecal weight, effects on various digestive organs, and effects on the metabolism of nutrients. Among these physiological activities, protein metabolism, lipid metabolism, and carbohydrate metabolism are also considered. There is a lot of research in the fields involved. In recent years, research on physiological effects of dietary fiber on bacterial groups in the intestine has also attracted attention. Dietary fiber is mainly contained in parts such as leaves, buds, stems, flowers, berries, roots, ears, seeds and fruits, which contain plant fibers, and is typically green plant powder.
• green plant powder a food material for producing so-called green juice is more preferable.
• examples thereof include a mixture of one or more of ashitapa powder, wheat leaf powder, green tea powder, and kale powder. It is.
• Other examples of green plants that can be used are described in many documents such as JP-A 2003-334046 and JP-A 2003-79339.
• Ashitapa powder by Japanese Patent Laid-Open No. 59-154935, Japanese Patent Laid-Open No. 2-231057, etc., and any dried ashitapa powder may be used regardless of its production method.
• Ashitaba is a perennial plant belonging to the celery family, and is cultivated in Japan in the central part of Honshu and in the waters near the Pacific side of the Kanto region.
• Vashitapa is rich in coumarins, chalcones, and other anti-acid vitamins and is effective for arteriosclerosis, constipation and anemia.
• the use site is not particularly limited, and all sites such as leaves, buds, stems and fruits can be used.
• the wheat leaf powder can be used in various ways according to publicly known literatures (JP 7-241176, JP 2001-112435, JP 2002-58449, JP 2002-212, JP 2003-9812, JP 2003-178). However, any dry wheat powder may be used.
• Wheat leaves are made of wheat This refers to young leaves, and specific examples include young leaves such as barley, wheat, rye, oats, and wheat. Wheat leaf is rich in vitamins, minerals, dietary fiber, etc., suppressing absorption of harmful substances, improving intestinal environment, suppressing absorption of cholesterol, preventing rapid increase in postprandial blood glucose level, activity of superoxide dismutase (SOD). It is attracting attention as a material for health foods that have effects such as mochi.
• SOD superoxide dismutase
• Kale powders are known literatures (JP 2002-186445, JP 2002-125612, JP 2002-119245, JP 2002-119239, JP 2002-112729, JP 2002-112701, JP Forces for which various production methods are known by 2002-85010) Any dry production method is acceptable as long as the production method is not limited.
• Kale is a perennial plant belonging to the Brassicaceae genus Brassica, originally an improved species of cabbage. The leaves are rich in vitamins and are effective in preventing gastritis and gastric ulcers, and improving liver function and constipation.
• Kale can be used without particular limitation as long as it belongs to the cruciferous kale.
• various canores such as siberian kale, scotch kale, and collard can be used.
• the powdered oral material to be granulated does not need to contain a commonly used binder, but if desired, hydroxypropylcellulose, hydroxypropylmethylcellulose, methylcellulose, carboxymethylcellulose, pullulan, starch, dextrin Or a binder selected from Gua Gumka.
• the content of the binder other than the oligosaccharide is 0 to 2% by weight in terms of the solid content of the oral composition after granulation.
• the powdered oral material to be granulated may further contain additives or auxiliary ingredients commonly used in foods, if necessary.
• sweeteners such as erythritol, xylitol, sorbitol, mantol, noratinite, maltitol, ratathitol, arabinose, galactose, darcos, fructose, aspartame, sucralose, stevia, etc.
• Isoflavones, chalcones, catechins, lycopene, rutin, austaxanthin, rutin and the like may also be included.
• the value as a foodstuff can be heightened by containing about 0.1 to 10 weight% of enzyme-treated rutin as an antioxidant component in terms of the solid content of the granulated oral composition.
• Enzyme-treated rutin is a glycoside obtained by enzymatic treatment of rutin and a rutin analogue. Quercetin, isoquercitrin, morin, myricitri as a rutin analogue. And myricetin.
• the enzyme-treated rutin can be obtained, for example, by the method described in JP-A-7-10898 and JP-A-2003-33164, and may contain not only the enzyme-treated rutin but also a pharmaceutically acceptable additive.
• the amount of enzyme-treated rutin per composition should be determined based on a daily intake of enzyme-treated rutin of 5 mg to 500 mg, preferably 10 mg to 300 mg per adult.
• the granulation step in the method of the present invention uses a fluidized bed granulation method that can be performed by any method including an extrusion granulation method and a fluidized bed granulation method to obtain granules having a good mouthfeel. It is desirable to do.
• the powdered oral material and, if used, additives or auxiliary ingredients are put into a fluid bed granulator and mixed.
• oligosaccharides with an aqueous solution of 5 to 40 wt 0/0 is sprayed into the fluidized bed granulator powder oral material. Operation conditions such as temperature and air volume during granulation can be set arbitrarily.
• the particles produced as described above are sifted through a No. 16 (aperture 1000 m) sieve as necessary to adjust the particle size to obtain an oral composition.
• the proportion of fine powder passing through a No. 325 (aperture 45 m) sieve is 50% by weight or less, preferably 25% by weight or less.
• the oral composition with a uniform particle size can be easily packaged according to the purpose of use.
• the oral composition obtained according to the present invention is a granule that does not easily scatter, it can be easily suspended in a liquid before ingestion, and has a good mouth feel when used as a suspension. It is.
• the aqueous liquid used for the preparation of the suspension is not particularly limited as long as it can be ingested orally, and examples thereof include milk drinks, soft drinks, alcoholic drinks and the like in addition to water.
• This oral composition has the advantage that the retention in the mouth is improved even when it is ingested in a granular state without being suspended in a liquid, and it is extremely easy to ingest!
• a preferred embodiment of the oral composition of the present invention is a granular food containing dietary fiber.
• the dietary fiber-containing food may be provided with a label regarding the function. There are no special restrictions on the method of displaying the function, but examples are food packaging, container surfaces, food instructions, and food advertisements.
• Examples of the functions of the dietary fiber-containing food of the present invention include prevention or improvement of symptoms such as arteriosclerosis, anemia, gastritis, gastric ulcer and constipation, improvement of liver function, Adsorption suppression of harmful substances, improvement of intestinal environment, diet effect, suppression of cholesterol absorption, prevention of rapid increase in postprandial blood glucose level, activation of superoxide dismutase, bifidobacterial activity such as growth control, colon cancer Functions based on prevention, mineral absorption promotion, or antioxidant action.
• Xylooligosaccharides, furato-oligosaccharides, mashitapa powder, barley young leaf powder, powdered green tea, enzyme-treated rutin, maltitol, eggshell calcium, kakukaku ganoderma powder and about 300 g of the mixed powder shown in Table 1 are made into a fluidized bed.
• granulator at (FD-LAB-1 (strain) Baurekku Ltd.) xylo-oligosaccharides 30 weight 0/0 solution as a spray solution, hydroxypropyl cellulose (HPC) 3 weight 0/0 soluble liquid, water, Furatatoorigo sugar 30 wt Granulate with any of the% solutions.
• the spray solution shown in Table 1 was granulated for 10 to 20 minutes while spraying at a rate of 1.0 to 1.5 mlZ (product temperature: 35 ° C to 40 °). C, intake air temperature: 50-60 ° C). After drying for 15 to 20 minutes in the same apparatus, the granulated product was taken out and sieved with a sieve of No. 16 (aperture 1000 m) to obtain granules.
• the proportion of fine powder was evaluated as an index of granulation, and the results are shown in Table 1. That is, when the proportion of fine powder passing through the No. 325 (opening 45 ⁇ m) is less than 25% by weight of the total amount, ⁇ when it is less than 50% by weight, and when it exceeds 50% by weight X It was. This was set in consideration of the handling of the granule and the mouthfeel during drinking.
• the granules produced in Examples 1 to 3 were orally ingested by 5 subjects in the form of granules and suspended in water, and the mouth feeling (roughness and sharpness) was evaluated.
• 3 points very bad mouth feeling
• 2 points bad mouth feeling
• 1 point slightly good mouth feeling
• 0 points good mouth feeling
• Table 1 The results are shown in Table 1, with an average of 3 or less and 2 or more, X, 2 or less, 1 or more, ⁇ , 1 or less, 0.
• Example 1 Example 2 Specimen No. 1 2 3 4 5 6 7 8 Xigokusai Rigo Sugar 15.0] 4.6 15.0 * 14.9 * 4.5 4.4 4.5 * 4.3 * Ashitaba powder 85.0 82.4 85.0 84.6 40.0 38.8 40.0 39.8 Solid Barley young leaf powder--- ⁇ 20.0 19.4 20.0 19.9 Type ⁇ 10.0 9.7 10.0 10.0 Quantity Matcha ⁇ ⁇ ⁇
• Test Example 3 As shown in the results of Sample Nos. 9 to 11, it was shown that granules having a good mouth feel can be obtained by using either a xylooligosaccharide solution or a fructooligosaccharide solution. .
• Granules were produced using the technique of the present invention.
• the amount of the granulation process is 100 kg, and each of the components shown in Table 2 is passed through a No. 16 (mesh size 1000 m) sieve and then fluidized bed granulator (Flow coater 200, manufactured by Front Industry Co., Ltd.) ).
• Flow coater 200 manufactured by Front Industry Co., Ltd.
• After preliminary flow was about 30 minutes granulated while spraying with key Shiroorigo sugar 30 wt 0/0 solution of about 800 ml / min (exhaust temperature: about 40 ° C, inlet air temperature: 60 ° C).
• the granulated product was taken out and sieved with a No. 16 sieve to obtain a granulated product.
• Barley young powder (weight 20. 0
• Example 4 As a result of the evaluation, it was shown that the granule obtained in Example 4 has a good mouthfeel.
• the oral composition according to the present invention can assist in eating habits as a food, a pharmaceutical, particularly a health food. Therefore, the present invention is used for industries in the field.
• an oligosaccharide solution as a binder for a powdered oral material, not only can it be molded (granulated) without using a binder other than oligosaccharide, but also a liquid suspension.
• a granular oral composition that has a good mouthfeel when cloudy and has improved oral retention when liquid is not suspended.
• the oral composition of the present invention is easy to handle, and the consumption of ingredients other than those intended for consumption by consumers is reduced.
• the oral composition of the present invention is imparted with the intestinal regulating action possessed by oligosaccharides, which is extremely useful for consumers in terms of health.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Animal Behavior & Ethology (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Natural Medicines & Medicinal Plants (AREA)
• General Chemical & Material Sciences (AREA)
• Epidemiology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Diabetes (AREA)
• Mycology (AREA)
• Microbiology (AREA)
• Medical Informatics (AREA)
• Botany (AREA)
• Alternative & Traditional Medicine (AREA)
• Biotechnology (AREA)
• Hematology (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Vascular Medicine (AREA)
• Urology & Nephrology (AREA)
• Obesity (AREA)
• Endocrinology (AREA)
• Emergency Medicine (AREA)
• Nutrition Science (AREA)
• Food Science & Technology (AREA)
• Polymers & Plastics (AREA)
• Gastroenterology & Hepatology (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Inorganic Chemistry (AREA)
• Medicinal Preparation (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=37481399

Family Applications (1)

Country Status (5)

Families Citing this family (10)

Citations (6)

• 2005
  • 2005-05-31 JP JP2005158628A patent/JP2006335648A/ja not_active Withdrawn
• 2006
  • 2006-05-11 CN CNA2006100783280A patent/CN1872342A/zh active Pending
  • 2006-05-15 TW TW095117132A patent/TW200718434A/zh unknown
  • 2006-05-15 WO PCT/JP2006/309628 patent/WO2006129468A1/ja not_active Ceased
  • 2006-05-15 KR KR1020077026508A patent/KR20080011389A/ko not_active Withdrawn

Patent Citations (6)

Also Published As

Similar Documents

Legal Events